A panel of biomarkers (CA 125, CYFRA 21-1, HER2 shed antigen, LDH, and CRP) in combination with CEA and CA 15-3 has been shown to increase the sensitivity of early detection of asymptomatic tumor recurrence in BC patients [29]. This evidence concerns the gene ERBB2 and breast cancer.